Financial Survey: Enovis (NYSE:ENOV) & ADB International Group (OTCMKTS:EQUR)

Enovis (NYSE:ENOVGet Free Report) and ADB International Group (OTCMKTS:EQURGet Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.

Institutional & Insider Ownership

98.4% of Enovis shares are held by institutional investors. 2.9% of Enovis shares are held by insiders. Comparatively, 79.6% of ADB International Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Enovis and ADB International Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Enovis -49.92% 10.32% 4.57%
ADB International Group N/A N/A N/A

Analyst Recommendations

This is a summary of recent recommendations and price targets for Enovis and ADB International Group, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enovis 1 1 7 1 2.80
ADB International Group 0 0 0 0 0.00

Enovis currently has a consensus price target of $41.86, indicating a potential upside of 48.39%. Given Enovis’ stronger consensus rating and higher possible upside, analysts clearly believe Enovis is more favorable than ADB International Group.

Earnings & Valuation

This table compares Enovis and ADB International Group”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Enovis $2.28 billion 0.71 -$1.18 billion ($19.88) -1.42
ADB International Group N/A N/A N/A N/A N/A

ADB International Group has lower revenue, but higher earnings than Enovis.

Summary

Enovis beats ADB International Group on 8 of the 10 factors compared between the two stocks.

About Enovis

(Get Free Report)

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

About ADB International Group

(Get Free Report)

E-Qure Corp., a medical device company, focuses on the development and commercialization of bioelectrical signal therapy (BST) devices. Its BST devices implement patented and proprietary electrical stimulation technologies to treat hard-to-cure wounds and ulcers up to complete closure and/or cure. The company was incorporated in 1988 and is based in New York, New York.

Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.